ClinicaliQ Trial Snapshot
- A 2-part Phase 1/2 Open-label Trial on ODM-212 — Recruiting • Phase I • Respiratory / COPD / Asthma • NCT07563738.
- What is being tested: ODM-212 is a novel therapeutic agent being evaluated through a structured phase 1/2 trial design, progressing from initial dose escalation to determine safety and tolerability, followed by dose expansion to optimise efficacy and establish recommended treatment protocols.
- Patient eligibility overview: The trial employs a multi-cohort, open-label design across multiple sites, allowing flexible recruitment of patient populations; specific eligibility criteria would determine whether patients have specific disease types, disease severity thresholds, or prior treatment requirements.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
Eligibility Snapshot
- : * Male or female participants ≥18 years old. * Performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. * Life expectancy of >12 weeks, in the opinion of the investigator. * Ability to take oral medications and willing to record daily adherence to investigational product. * Part 1: Participants with histologically or cytologically confirmed advanced or metastatic, unresectable solid tumors and who are able and willing to receive one of the anti-cancer therapies studied in this trial according to the investigator. * Arm A: Participants with histologically or cytologically confirmed diagnosis of advanced (unresectable or metastatic) mesothelioma who are eligible to receive treatment with ipilimumab/nivolumab; participants must not have undergone surgical therapy for mesothelioma. * Arm B: Participants with histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas who are eligible to receive treatment with nab-paclitaxel and gemcitabine. * Arm C: Participants with histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC and a KRAS G12C-mutation, confirmed using a validated test, who have received the available 1st line treatment and who are eligible for a treatment with sotorasib and have not received a KRAS G12C inhibitor as prior treatment. Part 2: * Ipilimumab/nivolumab…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.